Drug treatment of hypertension in older patients with diabetes mellitus

References

• Whelton PK, Carey RM, Aronow WS, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017 Nov 7:pii: S0735-1097(17)41519–1. [Epub ahead of print]. DOI:10.1016/j.jacc.2017.11.006
   Google Scholar
• Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419.
   PubMed Web of Science ®Google Scholar
• Oldridge NB, Stump TE, Nothwehr FK, et al. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle-and older-age adults. J Clin Epidemiol. 2001;54:928–934.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Hypertension and the older diabetic. Clin Geriatr Med. 2008;24:489–501.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol. 1996;77:864–866.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I, et al. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly Blacks and Whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991;67:295–299.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Elderly diabetics with peripheral arterial disease and no coronary artery disease have a higher incidence of new coronary events than elderly nondiabetics with peripheral arterial disease and prior myocardial infarction treated with statins and with no lipid-lowering drug. J Gerontol A Biol Sci Med Sci. 2003;58A:M573–5.
   Google Scholar
• Aronow WS, Ahn C, Gutstein H. Risk factors for new atherothrombotic brain infarction in 664 older men and 1,488 older women. Am J Cardiol. 1996;77:1381–1383.
   PubMed Web of Science ®Google Scholar
• Garland C, Barrett-Connor E, Suarez L, et al. Isolated systolic hypertension and mortality after age 60 years. Am J Epidemiol. 1983;118:365–376.
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research. Group: prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:3255–3264.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke. Am J Epidemiol. 1988;128:116–123.
   PubMed Web of Science ®Google Scholar
• Ness J, Aronow WS, Ahn C. Risk factors for peripheral arterial disease in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48:312–314.
   PubMed Web of Science ®Google Scholar
• Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand. 1982;211:249–256.
   PubMedGoogle Scholar
• Stokes J III, Kannel WB, Wolf PA, et al. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham study. Circulation. 1987;75(Suppl V):V65–73.
   PubMedGoogle Scholar
• Beach KW, Brunzell JD, Conquest LL, et al. The correlation of arteriosclerosis obliterans with lipoproteins in insulin-dependent and non-insulin-dependent diabetes. Diabetes. 1979;28:836–840.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest. 1999;115:867–868.
   PubMed Web of Science ®Google Scholar
• Sukhija R, Aronow WS, Kakar P, et al. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol. 2006;98:279–281.
   PubMed Web of Science ®Google Scholar
• Ravipati G, Aronow WS, Ahn C, et al. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up in patients with diabetes mellitus or systemic hypertension with and without microalbuminuria. Cardiology. 2008;109:62–65.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. J Am Geriatr Soc. 1998;46:1280–1281.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343–2349.
   PubMed Web of Science ®Google Scholar
• Larstorp AC, Okin PM, Devereux RB, et al. Changes inelectrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. J Hum Hypertens. 2011;25:178–185.
   PubMed Web of Science ®Google Scholar
• Larstorp AC, Okin PM, Devereux RB, et al. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic heart failure: the LIFE study. Am J Hypertens. 2012;25:1101–1109.
   PubMed Web of Science ®Google Scholar
• O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50:1–13.
   PubMed Web of Science ®Google Scholar
• Franklin SS. Elderly hypertensives: how are they different? J Clin Hypertens (Greenwich). 2012;14(11):779–786.
   PubMed Web of Science ®Google Scholar
• Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med. 2007;357(8):789–796.
   PubMedGoogle Scholar
• Mancia G, Giannattasio C. Diagnostic and therapeutic problems of isolated systolic hypertension. J Hypertens. 2015;33(1):33–43.
   PubMed Web of Science ®Google Scholar
• Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4(1):23–36.
   PubMedGoogle Scholar
• Davis BR, Langford HG, Blaufox MD, et al. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the hypertension detection and follow-up program experience. Circulation. 1987;75:340–346.
   PubMed Web of Science ®Google Scholar
• Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987–1996. Stroke. 2000;31:2307–2313.
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Nevitt MC, Yunis C, et al. Postural hypotension and postural dizziness in elderly women. The study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1992;152:1058–1064.
   PubMed Web of Science ®Google Scholar
• Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 1998;98:2290–2295.
   PubMed Web of Science ®Google Scholar
• Beck LH. The aging kidney: defending a delicate balance of fluid and electrolytes. Geriatrics. 2000;55(4):26–28,31 –2.
   PubMedGoogle Scholar
• Fliser D, Ritz E. Relationship between hypertension and renal function and its therapeutic implications in the elderly. Gerontology. 1998;44:123–131.
   PubMed Web of Science ®Google Scholar
• Stamler J, Rose G, Elliott P, et al. Findings of the international cooperative INTERSALT study. Hypertension. 1991;17:I9–15.
   PubMed Web of Science ®Google Scholar
• Rosenthal T, Shamiss A, Holtzman E. Dietary electrolytes and hypertension in the elderly. Int Urol Nephrol. 2001;33:575–582.
   PubMedGoogle Scholar
• Anderson DE, Parsons BA, McNeely JC, et al. Salt sensitivity of blood pressure is accompanied by slow respiratory rate: results of a clinical feeding study. J Am Soc Hypertens. 2007;1:256–263.
   PubMed Web of Science ®Google Scholar
• The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. J Clin Epidemiol. 1988;41:1197–1208.
   PubMed Web of Science ®Google Scholar
• Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284(4):465–471.
   PubMed Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276(23):1886–1892.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306(23):2588–2593.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid- lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–2997.
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989 Sep 28;321(13):868–873.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005 Jan 1;95(1):29–35.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832–842.
   PubMed Web of Science ®Google Scholar
• Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8(1):13–28.
   PubMed Web of Science ®Google Scholar
• Ram CV. Beta-blockers in hypertension. Am J Cardiol. 2010 Dec 15;106(12):1819–1825. [ Epub 2010 Nov 2].
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304. 405–412.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–1285.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354:1751–1756.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Grossman E, Goldbourt U. Are beta blockers efficacious as first line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903–1907.
   PubMed Web of Science ®Google Scholar
• Dahlöf, B., Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–1689.
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–1553.
   PubMed Web of Science ®Google Scholar
• William B, Lacy PS, Thom SM, et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225.
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017 Jan;20(1):CD002003.
   Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10–16;366(9489):895–906.
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006 Jan;24(1):3–10.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control, QJM. An International Journal of Medicine. 2006 July 1;99(7):431–436.
   Google Scholar
• Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press. 1999;8(5–6):261–268.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–764.
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160:211–220.
   PubMedGoogle Scholar
• Gong, L., Zhang W, Zhu Y,et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14:1237–1245.
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000 Jul 29;356(9227):359–365.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA. 2003;290:2805–2816.
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.
   PubMed Web of Science ®Google Scholar
• Ostergren J, Poulter NR, Sever PS, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens. 2008 Nov;26(11):2103–2111.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366–372.
   PubMed Web of Science ®Google Scholar
• Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998 Apr;21(4):597–603.
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Yusuf S, Sleight P, Bosch J, et al. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145–153. [Erratum, N Engl J Med 2000; 342:784,1376.].
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Mann JFE, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259. [Erratum,Lancet 2000;356:860.].
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24(11):2163–2168.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–207.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010;24:600–608.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus. Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventative Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–2114.
   PubMedGoogle Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–2219.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311:507–520.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528–542.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. London, UK: National Institute for Health and Clinical Excellence; 2011.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36(Suppl 1):S11–S66.
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Lackland DT, Allison M, et al. AHA/ACC/ASH scientific statement. treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65(18):1998–2038.
   Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14–26.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA. 2015;313:603–615.
   PubMed Web of Science ®Google Scholar
• Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CD008277.
   PubMed Web of Science ®Google Scholar
• Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–443.
   PubMed Web of Science ®Google Scholar
• Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185:949–957.
   PubMed Web of Science ®Google Scholar
• Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. Br Med J. 2016;352:i717.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957–967.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017 Jun;130(6):707–719.e8.
   PubMed Web of Science ®Google Scholar
• Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017 Jul 1;2(7):775–781.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes. N Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721–1728.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: action to control cardiovascular risk in diabetes blood pressure trial. Hypertension. 2015;66:1123–1129.
   PubMed Web of Science ®Google Scholar
• Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401–1408.
   Web of Science ®Google Scholar
• Buckley LF, Dixon DL, Wohlford GF 4th, et al. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. Diabetes Obes Metab. 2018 Feb 9. [ Epub ahead of print]. DOI:10.1111/dom.13248
   Google Scholar
• Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005 Jun 27;165(12):1410–1419.
   PubMedGoogle Scholar
• Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005 Jun 27;165(12):1401–1409.
   PubMedGoogle Scholar
• Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–2056.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May;19(338):b1665.
   Google Scholar
• Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010;Nov;11(16):2599–2607.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Frishman WH. Implications of the new national guidelines for hypertension. Cardiol Rev. 2018 Mar/Apr;26(2):55–61.
   PubMed Web of Science ®Google Scholar
• Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124(1727–36):28.
   Google Scholar
• Bakris GL. The implications of blood pressure measurement methods on treatment targets for blood pressure. Circulation. 2016;134:904–905.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Gao HK, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017 May 25;6(6):pii: e004007.
   PubMed Web of Science ®Google Scholar
• Goud A, Zhong J, Peters M, et al. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016 Feb;18(2):16.
   PubMed Web of Science ®Google Scholar